Baird raised the firm’s price target on Soleno Therapeutics (SLNO) to $102 from $72 and keeps an Outperform rating on the shares. The frim raised its target sas the FDA approval of its drug for hyperphagia may transform the PWS landscape.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Aardvark Therapeutics price target raised to $26 from $22 at BofA
- Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug
- Closing Bell Movers: Stock futures, Big Three automakers fall on auto tariffs
- Soleno Therapeutics announces FDA approval of VYKAT XR to treat hyperphagia
- Soleno Therapeutics up 35% afterhours following resumption of trading